Science 37’s technology platform, supported by our specialized networks, makes it easier to access virtually any patient, anywhere, by bringing the trial directly into the patient's home.

These specialized networks help operationalize, conduct, and support studies. This is done by creating a personalized clinical trial journey for the patient with easy-to-use technology, telemedicine and remote visits planned around the patient’s schedule.

A Science 37 Metasite enables more access for patients and physicians, while also collecting the same study data as other sites more efficiently. You’ll also gain a more representative, hard-to-reach patient population, and mitigate risk from unforeseen issues to ensure business continuity.

Enable your research using the platform that has fueled more decentralized trials than any other. This fully configurable system  is available as a standalone solution or coupled with our suite of SaaS. It provides you with comprehensive, end-to-end trial management to orchestrate workflow, generate evidence, and harmonize data from eSources (eCOA/ePRO), real-world evidence (RWE), and wearable devices.

The Science 37 Operating System™ (OS) supports any phase of a study — including pivotal trials or real-world evidence (RWE) studies — for any number of indications. These include oncology, CNS, endocrinology, pediatrics, and infectious and rare diseases.

We’ve successfully supported sponsors from biotech and big pharma and their CROs in enabling greater patient recruitment, at scale, globally.

The Science 37 OS enables access to patients and providers, leading to faster enrollment, greater retention, and a more representative patient population.

We launched our Diversity in Clinical Trials business unit with one goal—to drive diversity, access, and equity in clinical research.

We deliver agile clinical trials, integrating decentralized trial elements with traditional clinical sites. This enables universal access to patients and providers.